-+ 0.00%
-+ 0.00%
-+ 0.00%

Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation

PUBT·08/31/2026 08:34:37
Listen to the news
Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation
  • Wholly owned unit Shandong Zibo Xincat Pharmaceutical cleared China generics consistency evaluation for azithromycin tablets in August 2026.
  • Regulator issued a supplementary drug application approval notice for 0.25g tablets under China approval number H20083479.
  • Azithromycin tablet sales in China public medical institutions totaled about RMB 670 million in 2025, providing a market benchmark.
  • Clearance expected to lift Xincat’s competitiveness in hospital tenders, though pricing and procurement policy shifts remain a key risk.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12307971), on August 31, 2026, and is solely responsible for the information contained therein.